New
HealthMore in Health →
MD Anderson team identifies YAP1 as a marker of chemotherapy resistance in relapsed lung cancer
Researchers at MD Anderson Cancer Center report that some relapsed lung cancer cells switch on YAP1 only after chemotherapy, a finding that could help explain why treatment-resistant disease returns.
Key Takeaways
- MD Anderson researchers identified YAP1 as a biomarker associated with chemotherapy resistance in relapsed lung cancer.
- The report says some cancer cells express YAP1 only after treatment, helping them survive.
DE
DT Editorial AI··via medicalxpress.com